{"analyses":[{"ciLowerLimit":"0.313","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.653","estimateComment":"Hazard ratio was based on an unstratified Cox proportional hazard regression model and treatment as a factor in the model.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.436","pValueComment":"P-value is from an unstratified log-rank test.","paramType":"Hazard Ratio (HR)","paramValue":"0.719","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of 95% CI was not estimable due to low number of participants with the event.","groupId":"OG000","lowerLimit":"8.31","upperLimit":"NA","value":"12.9"},{"comment":"The upper limit of 95% CI was not estimable due to low number of participants with the event.","groupId":"OG001","lowerLimit":"10.15","upperLimit":"NA","value":"18.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"description":"Duration of CR is first documented CR to the first documentation of PD or relapse from CR (participants with low-blast AML). Disease responses (HR MDS/CMML) are based on modified IWG response criteria for MDS and for low-blast AML on revised IWG response criteria for AML. For HR MDS/CMML-CR:\\<=5%myeloblasts with normal maturation of all bone marrow cell lines, \\>=11 g/dL Hb, \\>=100\\*10\\^9/L plt,\\>=1.0\\*10\\^9/L neutrophils, 0% blasts in peripheral blood;PR: all CR criteria met except bone marrow blasts \\>=50% decrease over pretreatment but still \\>5%; low-blast AML-CR: morphologic leukemia-free state, \\>1.0\\*10\\^9/L ANC ,plt \\>=100\\*10\\^9/L,transfusion independence, no residual evidence of extramedullary leukemia;CR with incomplete blood count recovery:fulfill CR criteria except residual neutropenia \\<1.0\\*10\\^9/L/TTP \\<100\\*10\\^9/L;PR:all CR hematological values but with a decrease of \\>=50% in blasts percentage to 5%-25% in bone marrow aspirate.","dispersionType":"Full Range","groups":[{"description":"Azacitidine 75 mg/m\\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).","id":"OG000","title":"Azacitidine 75 mg/m^2"},{"description":"Azacitidine 75 mg/m\\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 and pevonedistat 20 mg/m\\^2, infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).","id":"OG001","title":"Azacitidine 75 mg/m^2 + Pevonedistat 20 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"REP included all participants who received at least 1 dose of study drug and had a Baseline and at least 1 postbaseline disease assessment. Data is reported for the responders with complete CR and PR.","reportingStatus":"POSTED","timeFrame":"From date of randomization until CR or PR (up to approximately 5 years)","title":"Duration of Complete Remission (CR) and Partial Remission (PR)","type":"SECONDARY","unitOfMeasure":"months"}